FDA Approves First DNA Medicine as Inovio Shares Soar 257% on Voceryq Nod

The U.S. Food and Drug Administration on Friday, October 30, granted accelerated approval to Voceryq, a treatment for adults with recurrent respiratory papillomatosis (RRP). The decision matters well beyond one rare airway disease. According to the FDA’s announcement, it is the first plasmid DNA-based immunotherapy approved in the United States, and its developer, Inovio Pharmaceuticals, calls it the first FDA-approved DNA medicine of any kind.

Investors noticed immediately. Reuters reported that Inovio shares were up 257% in extended trading after the news, since Voceryq is the company’s first approved product after years of development.

What Voceryq Treats

RRP is a rare, chronic disease in which wart-like growths called papillomas form in the airway, most often on and around the vocal cords. The FDA says the growths are caused by human papillomavirus (HPV) types 6 and 11 and can lead to hoarseness, chronic cough and voice changes, and in severe cases can spread through the respiratory tract and make breathing difficult. In some cases the disease can become cancerous over time.

Until now, the standard of care has been surgery to cut the growths out. The problem is that surgery removes the symptom, not the cause. The virus stays in the tissue, so the papillomas tend to come back, and patients can face repeated procedures for years. Each operation carries a risk of permanent damage to the vocal cords. Inovio estimates, based on its analysis of claims data, that at least 25,000 people in the United States are living with RRP.

How the DNA Medicine Works

Voceryq delivers two small circular pieces of DNA, called plasmids, into the body’s cells. One carries genetic instructions for specific HPV-6 and HPV-11 proteins; the other encodes IL-12, a molecule that strengthens the immune response. The goal is to train the immune system to find and attack the infected cells that keep producing new growths.

Delivery is unusual. The therapy is injected into muscle using Inovio’s CELLECTRA 5PSP device, which applies brief electrical pulses, a technique called electroporation, to open temporary pores in cell membranes so the DNA can get inside. Inovio says the approach needs no chemical adjuvants or lipid nanoparticles. After a standard surgical removal of visible growths, the dosing regimen runs nine weeks, and no extra surgery is required during that window.

The Clinical Evidence

The approval rests on a single open-label, multicenter trial in 32 adults who had needed at least two surgeries in the prior year. According to Inovio’s release, 26 of those patients had needed three or more surgeries in the previous 12 months, with a median of 4.5 procedures. Seven of those 26 patients, or 27%, needed no surgery at all in the year after treatment.

Those figures deserve a measured reading. The study was small and had no control arm, and Inovio’s own 95% confidence interval for that 27% runs from 12% to 48%. That is exactly why the FDA used its accelerated approval pathway, which allows a decision based on an intermediate endpoint, here fewer surgeries, that is “reasonably likely” to predict real clinical benefit. Inovio must run a confirmatory study; the FDA wants a draft protocol by the end of 2026, with a final design expected by mid-2027.

On safety, the most common reactions reported were injection site reactions, headache, fatigue, high blood pressure, nausea and dizziness. Inovio says most treatment-related reactions were mild to moderate and temporary, and all 32 patients completed the study. The label warns about electroporation-related effects such as brief muscle contractions and fainting-type reactions, and advises avoiding use in patients with certain implants or pacemakers near the treatment site.

Why It Matters for Business Readers

Platform validation is the real prize. For a biotech company, the first approval proves that regulators will accept its underlying technology, not only a single drug. Inovio frames Voceryq as validation of its DNA medicine platform, which it is also developing for HPV-related diseases, cancer and infectious diseases. That is a big part of why a rare-disease approval moved the stock so sharply.

Rare diseases remain a viable commercial path. The FDA had given Voceryq both Breakthrough Therapy and Orphan Drug designations. Orphan status brings incentives designed to make small patient populations worth serving, and this approval is another example of companies using a rare indication as the first commercial foothold for a broader platform.

Execution now matters more than science. Inovio says the therapy should be available to order and ship in about 60 days, with full commercial launch in the first quarter of 2027, and it has hired Syneos Health to help build its medical and commercial field teams. Pricing was not disclosed in the FDA or company announcements, and the company plans to share more on the label and commercialization on a conference call on Monday, November 2, at 8:00 AM ET. Launching a first product that relies on a specialized device will test Inovio’s ability to train clinicians, win insurer coverage and move patients away from a long-established surgical routine.

Surgery-heavy care models could shift. Dr. Simon Best of Johns Hopkins, a lead investigator on the trial, said in Inovio’s release that he believes the standard of care should move quickly from surgery to immunotherapy after diagnosis. If that view spreads, hospitals and specialists who treat RRP could see procedure volumes change, while payers will weigh the drug’s cost against fewer operations.

The Bottom Line

Voceryq is a milestone for DNA medicine: a first-of-its-kind approval that gives RRP patients a nonsurgical option aimed at the virus behind their disease. It is also a conditional win. The supporting data are early, the confirmatory trial is still ahead, and commercial success will depend on launch execution and reimbursement. For investors and healthcare leaders, the next signals to watch are the November 2 call, the drug’s price, and how quickly specialists adopt it in early 2027.

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous

---

Edited by Palawan @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous